Superoxide dismutase skin spray to prevent radiation skin damage in head and neck cancer
Tests a superoxide dismutase skin spray against placebo in people having head and neck radiotherapy.
Plain-language title generated from the registry record
Registry title: Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer
Key facts
- Where
- Chengdu, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07704372, who can take part
Where in China
- Sichuan University West China HospitalChengdu, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- West China Hospital
- Trial code
- NCT07704372
- Record updated
- 29 October 2026
- Original description
To evaluate the efficacy and safety of superoxide dismutase skin spray for the reducing the acute radiation dermatitis in patients with head and neck malignancies undergoing radiotherapy.Read full original descriptionShow less
Superoxide Dismutase Skin Spray for Reducing Acute Radiation Dermatitis in Patients With Head and Neck Cancer Undergoing Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
To evaluate the efficacy and safety of superoxide dismutase skin spray for the reducing the acute radiation dermatitis in patients with head and neck malignancies undergoing radiotherapy.
Inclusion: Histologically confirmed malignant tumors of the head and neck without distant metastasis; Scheduled to undergo either postoperative adjuvant radiotherapy or definitive radiotherapy, with or without concurrent chemotherapy; Age 18-80 years at the time of consent; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Signed informed consent form; Adequate cognitive and reading abilities to complete the questionnaire.
Exclusion: Pre-existing skin disease or open wounds in the irradiation field; Have a history of head and neck radiotherapy; Autoimmune or connective tissue disorders affecting skin; Known allergy to any component of study formulations; Any condition that, in the investigator's judgment, would interfere with study participation or outcome assessment.